Zai Lab (ZLAB) CLO sells 8,651 ADS under Rule 10b5-1 plan

Rhea-AI Filing Summary

Zai Lab Ltd's Chief Legal Officer, identified as an officer of the company, reported an open-market sale of company stock. On 12/16/2025, the reporting person sold 8,651 American Depositary Shares (ADS) of Zai Lab at a price of $17.14 per ADS, as shown in Table I with transaction code "S" for a sale.

After this transaction, the reporting person beneficially owns 19,086 ADS, held directly. Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are fully fungible. The filing notes that this sale was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, indicating the trade was pre-arranged under that plan.

Insider Trade Summary

Net Seller: 8,651 shares ($148,278)

Net Sell 1 txn

Insider Edmondson Frazor Titus III

Role Chief Legal Officer

Sold 8,651 shs ($148K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	8,651	$17.14	$148K

Holdings After Transaction: American Depositary Shares — 19,086 shares (Direct)

Footnotes (1)

1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edmondson Frazor Titus III

(Last) (First) (Middle)

C/O ZAI LAB LIMITED

314 MAIN STREET, 4TH FLOOR, SUITE 100

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zai Lab Ltd [ ZLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares(1)	12/16/2025		S(2)		8,651	D	$17.14	19,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

	/s/ Bruce Blefeld, Attorney-in-Fact	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zai Lab (ZLAB) report in this Form 4?

The Chief Legal Officer of Zai Lab Ltd reported selling 8,651 American Depositary Shares (ADS) of the company on 12/16/2025 in an open-market sale.

At what price were the Zai Lab (ZLAB) ADS sold and how many shares remain?

The reporting person sold the 8,651 ADS at a price of $17.14 per ADS and now beneficially owns 19,086 ADS directly following the transaction.

Who is the insider involved in this Zai Lab (ZLAB) stock transaction?

The insider is an officer of Zai Lab Ltd, serving as the company's Chief Legal Officer, as indicated in the relationship section of the filing.

Was the Zai Lab (ZLAB) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was effected under a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.

What does each Zai Lab (ZLAB) American Depositary Share represent?

Each American Depositary Share (ADS) of Zai Lab represents ten Ordinary Shares, and the ADSs and Ordinary Shares are described as fully fungible.

Is this Zai Lab (ZLAB) Form 4 filed by one or multiple reporting persons?

The document indicates that the Form 4 is filed by one reporting person, not a group, as shown by the checked box in the filing.